599 results on '"Voest, Emile"'
Search Results
2. Optimized whole-genome sequencing workflow for tumor diagnostics in routine pathology practice
3. Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial
4. Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial
5. Agnostic drug development revisited
6. Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP)
7. Identification of patient-specific CD4+ and CD8+ T cell neoantigens through HLA-unbiased genetic screens
8. Functional precision oncology using patient-derived assays: bridging genotype and phenotype
9. A pan-cancer analysis of the microbiome in metastatic cancer
10. Impact of genetic counseling strategy on diagnostic yield and workload for genome-sequencing-based tumor diagnostics
11. Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
12. γδ T cells are effectors of immunotherapy in cancers with HLA class I defects
13. Taxanes trigger cancer cell killing in vivo by inducing non-canonical T cell cytotoxicity
14. Identifying somatic changes in drug transporters using whole genome and transcriptome sequencing data of advanced tumors
15. RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells
16. Delivering precision oncology to patients with cancer
17. The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology
18. Limited evolution of the actionable metastatic cancer genome under therapeutic pressure
19. Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy.
20. Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery Protocol.
21. Enhancing radiation response by a second-generation TRAIL receptor agonist using a new in vitro organoid model system
22. Preferences to receive unsolicited findings of germline genome sequencing in a large population of patients with cancer
23. Caring for patients with cancer in the COVID-19 era
24. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
25. Tumor organoid–T-cell coculture systems
26. Pan-cancer whole-genome analyses of metastatic solid tumours
27. When oncologic treatment options outpace the existing evidence: Contributing factors and a path forward
28. Author Correction: The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology
29. Is It Our Duty To Hunt for Pathogenic Mutations?
30. The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies
31. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers
32. Study protocol: Whole genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE)
33. Tumor Organoids as a Pre-clinical Cancer Model for Drug Discovery
34. Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours
35. Partner independent fusion gene detection by multiplexed CRISPR-Cas9 enrichment and long read nanopore sequencing
36. The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact
37. Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma
38. Molecular tumour boards and molecular diagnostics for patients with cancer in the Netherlands: experiences, challenges, and aspirations
39. Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab
40. Phase I study of combined indomethacin and platinum-based chemotherapy to reduce platinum-induced fatty acids
41. Cancer patients’ intentions towards receiving unsolicited genetic information obtained using next-generation sequencing
42. Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers
43. Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO)
44. ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016
45. Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma
46. Precision cancer medicine: Concepts, current practice, and future developments.
47. Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases
48. Author Correction: Caring for patients with cancer in the COVID-19 era
49. Distinct phosphatases antagonize the p53 response in different phases of the cell cycle
50. Identification of patient-specific CD4+ and CD8+ T cell neoantigens through HLA-unbiased genetic screens.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.